Email this article Bisfosfonaty - novye grani aktivnosti
- Authors: Bolotina LV1
-
Affiliations:
- ФГУ Московский научно-исследовательский онкологический институт им. П. А. Герцена Росмедтехнологий
- Issue: Vol 15, No 4 (2010)
- Pages: 49-51
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/39848
- DOI: https://doi.org/10.17816/onco39848
- ID: 39848
Cite item
Full Text
Abstract
The paper shows that bisphosphonates are now an integral part in the complex treatment of bone metastases. Their use reduces a risk for development of fractures, including those with spinal cord compression and hypercalcemia. The additional property of bisphosphonates is their ability to prevent bone mineral density loss during hormonal therapy with tamoxifen and aromatase inhibitors. There has been more and more information on the antitumor activity of bisphosphonates, as demonstrated by the ABCSG-12 study of zoledronate used in 1800 patients with early breast cancer. This property of bisphosphonate is also confirmed by the AZURE study in which addition of bisphosphonates to the standard neoadjuvant chemotherapy could increase the frequency of beneficial effects. Addition of bisphosphonates to chemotherapy or hormonal therapy improves the results of treatment and quality of life in cancer patients.
Keywords
About the authors
L V Bolotina
ФГУ Московский научно-исследовательский онкологический институт им. П. А. Герцена Росмедтехнологий
Email: mnioi@mail.ru
д-р мед. наук, рук. отд-ния химиотерапии; ФГУ Московский научно-исследовательский онкологический институт им. П. А. Герцена Росмедтехнологий
References
- Berenson J. R., Lichtenstein A., Porter L. et al. // J. Clin. Oncol. - 1998. - Vol. 16, N 2. - P. 593-602.
- Coleman R. E. // Cancer Treat. Rev. - 2001. - Vol. 27, N 3. - P. 165-176.
- Coleman R. E. // Semin. Oncol. - 2007. - Vol. 34, N 6. - Suppl. 4. - P. S11-S16.
- Gnant M., Mlineritsch B.l, Schippinger W. et al. // 44-th Annual Meeting of the American Society of Clinical Oncology. - Chicago, 2008. - Abstr.LBA4.
- Lipton A. et al. // Cancer. - 2000. - Vol. 88. - P. 1082-1090.
- Mundy G. R. // Nat. Rev. Cancer. - 2002. - Vol. 2, N 8. - P. 584-593.
- Rosen L. S., Gordon D., Tchekmodyan S. et al. // J. Clin. Oncol. - 2003. - Vol. 21. - P. 3150-3157.
- Saad F., Gleason D. M., Murray R. t al. // J. Natl. Cancer Inst. - 2004. - Vol. 96. - P. 879-882.
- Santini D., Vincenzi B., Dicuonzo G. et al. // Clin. Cancer Res. - 2003. - Vol. 9. - P. 2893-2897.
- Santini D., Martini F., Fratto M. E. et al. // Cancer Immunol. Immunother. - 2008. - May 6.
- Senaratne S. G., Pirianov G., Mansi J. L. et al. // Br. J. Cancer. - 2000. - Vol. 82. - P. 1459-1468.
- Winter M. C. et al. // 32-nd Annual CTRC-AACR San Antonio Breast Cancer Symposium. - San Antonio, 2008. - Abstr. 5101.
Supplementary files
